Glucose-lowering drugs for diabetes can be divided into two categories: oral and injectable preparations, and oral drugs include seven categories: 1. metformin is the first-line glucose-lowering drug for patients with type 2 diabetes; 2. sulfonylureas can promote insulin secretion, such as gliclazide, glipizide, glimepiride; 3. glinides can also promote insulin secretion, such as repaglinide and nateglinide; 4. glycosidase inhibitors can delay the conversion of carbohydrates to glucose, such as acarbose and voglibose; 5. 4. Glucosidase inhibitors can delay the conversion of carbohydrates to glucose, such as acarbose and voglibose; 5. Glitazones can increase insulin sensitivity, such as rosiglitazone and pioglitazone; 6. Dipeptidyl peptidase 4 inhibitors, referred to as DPP-4 inhibitors, can reduce the breakdown of endogenous glucagon-like peptide-1 (GLP-1), such as selegiline and ligliptin; 7. Sodium-glucose co-transport protein 2 inhibitors, referred to as SGLT -2 inhibitors, which can inhibit the reabsorption of glucose by the renal tubules such as dagliflozin and enagliflozin. The above are oral hypoglycemic drugs, and injectable preparations include: 1) insulin can supplement endogenous insulin secretion deficiency; 2) glucagon-like peptide-1 receptor agonists, referred to as GLP-1 receptor agonists such as liraglutide, exenatide, dulcolactone, etc. The mechanism of action of each type of drugs is different, and the population is not quite the same, so the doctor needs to choose them according to the patient’s condition.